Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced that all resolutions proposed at its Annual General Meeting on May 13, 2025, were passed, including the re-election of directors and the re-appointment of auditors. The approval of these resolutions supports the company’s governance and operational continuity, potentially strengthening its position in the biopharmaceutical industry.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.